Meropenem & Vaborbactam
- TRADE NAME: Vabomere (Rempex)
- INDICATIONS: Complicated urinary tract infections caused by susceptible bacteria
- CLASS: Antibiotic, Antibiotic; carbapenem (meropenem), Antimicrobial, Beta-lactamase inhibitor (vaborbactam)
- HALF-LIFE: 1–2 hours
FDA APPROVAL DATE: 08/29/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: N/A
Potential risk to fetus based on animal studies
See also separate entry for meropenem.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
LOCAL.
OTHER.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
